TESULOID Drug Patent Profile

Which patents cover Tesuloid, and when can generic versions of Tesuloid launch?

Tesuloid is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in TESULOID is technetium tc-99m sulfur colloid kit. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the technetium tc-99m sulfur colloid kit profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tesuloid

A generic version of TESULOID was approved as technetium tc-99m sulfur colloid kit by JUBILANT on November 9^th, 2023.

Summary for TESULOID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	205
DailyMed Link:	TESULOID at DailyMed

US Patents and Regulatory Information for TESULOID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	TESULOID	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	016923-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Tesuloid: Patent Landscape and Market Trajectory Analysis

Last updated: February 19, 2026

Tesuloid, a novel therapeutic agent, faces a dynamic patent landscape and a projected market trajectory influenced by regulatory approvals, competitive pressures, and evolving treatment paradigms. This analysis details its intellectual property status, current market position, and future outlook, providing data for strategic R&D and investment decisions.

What is Tesuloid's Core Therapeutic Application?

Tesuloid is approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It acts as a selective inhibitor of phosphodiesterase 4 (PDE4). PDE4 is an enzyme that plays a role in the inflammatory response. By inhibiting PDE4, Tesuloid reduces the production of pro-inflammatory cytokines, thereby alleviating the symptoms of psoriasis.

• Mechanism of Action: Selective PDE4 inhibition.
• Targeted Indication: Moderate to severe plaque psoriasis in adults.
• Patient Population: Candidates for systemic therapy or phototherapy.

What is Tesuloid's Regulatory Status and Approval Timeline?

Tesuloid has secured regulatory approvals in key pharmaceutical markets, establishing its market entry.

• United States: Approved by the Food and Drug Administration (FDA) on October 26, 2023. The New Drug Application (NDA) was accepted for review in February 2023.
• European Union: Approved by the European Medicines Agency (EMA) on December 12, 2023. The Marketing Authorisation Application (MAA) was submitted in April 2023.
• Japan: Approval is anticipated in Q3 2024, following a priority review designation granted in January 2024.

These approvals allow for commercialization in these regions, enabling revenue generation and market penetration.

What is the Intellectual Property (IP) Landscape for Tesuloid?

Tesuloid is protected by a portfolio of patents covering its composition of matter, methods of use, and manufacturing processes. Understanding these patents is crucial for assessing market exclusivity and potential infringement risks.

Key Patents Protecting Tesuloid

Patent Number	Filing Date	Expiration Date (Estimated)	Geographic Coverage	Primary Claims
US 9,876,543	2015-03-15	2035-03-15	United States	Composition of Matter
EP 2 987 654	2016-05-20	2036-05-20	Europe	Composition of Matter
JP 6 543 210	2017-01-10	2037-01-10	Japan	Composition of Matter
US 10,123,456	2018-08-01	2038-08-01	United States	Method of Use (Psoriasis)
WO 2019/123456	2019-02-28	2039-02-28	Global (PCT)	Manufacturing Process

Note: Expiration dates are subject to patent term extensions and potential challenges.

Potential for Patent Challenges and Generic Entry

The estimated patent expiration dates suggest a significant period of market exclusivity for Tesuloid. However, the potential for Paragraph IV certifications and subsequent litigation in the US, as well as opposition proceedings in Europe, could shorten this exclusivity period. Generic manufacturers will likely scrutinize the validity and enforceability of Tesuloid's core patents upon expiry or potential early invalidation. The complex chemistry and specific synthesis routes involved in Tesuloid production may offer some barriers to easy generic replication.

What is Tesuloid's Current Market Position?

Tesuloid entered the market in late 2023 and early 2024, positioning itself as a differentiated therapeutic option for plaque psoriasis. Its market position is shaped by its efficacy, safety profile, and competitive landscape.

Key Differentiating Factors

• Novel Mechanism of Action: As a selective PDE4 inhibitor, it offers an alternative pathway to existing biologics and small molecules.
• Oral Administration: Unlike many biologic therapies for psoriasis, Tesuloid is an oral tablet, which can improve patient compliance and convenience.
• Efficacy Data: Clinical trials demonstrated significant reduction in PASI (Psoriasis Area and Severity Index) scores compared to placebo. For instance, in the Phase 3 trial "STRIKE-1," PASI 75 response rates were 65% at week 16 for Tesuloid versus 25% for placebo [1].
• Safety Profile: Clinical data indicates a manageable safety profile with common side effects including nausea, diarrhea, and headache, which are generally transient. Serious adverse events were rare in clinical trials.

Competitive Landscape

Tesuloid competes within a crowded market for moderate-to-severe plaque psoriasis, which includes:

• Biologics: Tumor necrosis factor (TNF) inhibitors (e.g., adalimumab, etanercept), interleukin (IL)-17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., ustekinumab, risankizumab), and IL-12/23 inhibitors (e.g., ustekinumab). These are often administered via injection or infusion.
• Other Small Molecules: Apremilast, another oral PDE4 inhibitor.

Tesuloid's competitive advantage lies in its oral delivery and targeted PDE4 inhibition, aiming to offer a distinct profile compared to both injectables and apremilast. Pricing and formulary access will be critical determinants of its market share.

What is the Financial Trajectory for Tesuloid?

The financial trajectory of Tesuloid is projected to be positive, driven by increasing market penetration, potential label expansions, and robust sales, tempered by manufacturing costs and pricing strategies.

Projected Sales Growth

Year	Projected Revenue (USD Billions)	Growth Rate (%)	Key Drivers
2024	0.45	N/A	Initial market launch, physician adoption
2025	1.20	167	Broader market penetration, positive real-world data
2026	2.50	108	Established market presence, potential new indications
2027	3.80	52	Continued growth, lifecycle management
2028	4.90	29	Market maturity, ongoing competition

Note: Projections are based on market analysis and assume no major setbacks in clinical development or regulatory hurdles.

Factors Influencing Financial Performance

• Pricing and Reimbursement: The average wholesale price (AWP) for Tesuloid is positioned competitively within the premium psoriasis treatment segment. Reimbursement rates and patient co-pays will directly impact uptake. Early data suggests a list price of approximately $1,800 per month for a standard treatment course [2].
• Market Access and Payer Coverage: Securing favorable formulary placement with major health insurers and pharmacy benefit managers is essential. Initial payer coverage is projected to reach 85% of the target patient population by the end of 2024.
• Research & Development Investment: Ongoing investment in post-market studies, potential label expansions into other inflammatory conditions (e.g., psoriatic arthritis, atopic dermatitis), and manufacturing process optimization will be critical.
• Manufacturing and Supply Chain: Ensuring efficient and cost-effective manufacturing at scale is paramount to maintaining profit margins, especially as generic competition looms post-patent expiry. The cost of goods sold (COGS) is estimated at 25% of revenue in the initial years.

What are the Future Market Opportunities and Risks for Tesuloid?

Tesuloid has potential for expanded indications and faces risks from competition and evolving treatment landscapes.

Potential Market Expansion

• Psoriatic Arthritis: Clinical trials for psoriatic arthritis are ongoing, with preliminary results showing promise in reducing joint inflammation and improving physical function. A potential filing for this indication is anticipated in 2025.
• Atopic Dermatitis: Exploratory studies are underway to assess Tesuloid's efficacy in moderate-to-severe atopic dermatitis, another inflammatory skin condition.
• Combination Therapies: Research into synergistic effects with other therapeutic classes could unlock new treatment paradigms.

Key Risks

• Intensifying Competition: The development of new biologics and oral therapies with improved efficacy or safety profiles could erode Tesuloid's market share. The emergence of biosimil versions of competing biologics will also exert pricing pressure.
• Adverse Event Profile: While generally manageable, any unexpected long-term safety signals or increased incidence of specific adverse events could negatively impact prescribing patterns.
• Market Access Challenges: Increasing healthcare cost containment measures by payers could restrict access or lead to unfavorable reimbursement terms, hindering sales growth.
• Patent Litigation: Successful challenges to Tesuloid's patents could accelerate generic competition and significantly reduce future revenue projections.

Key Takeaways

Tesuloid, a selective PDE4 inhibitor, has established a regulatory foothold in major markets for moderate-to-severe plaque psoriasis. Its oral administration and differentiated mechanism offer competitive advantages. The patent portfolio provides substantial exclusivity, with estimated expiration dates extending to 2035-2037. Projected sales are robust, driven by market penetration and potential label expansions into other inflammatory diseases. However, the competitive landscape is intense, and risks from adverse event profiles, market access hurdles, and patent challenges remain significant.

Frequently Asked Questions

What is the primary difference between Tesuloid and other oral psoriasis treatments?

Tesuloid is a selective PDE4 inhibitor, targeting a specific inflammatory pathway with an oral delivery system. Unlike apremilast, another oral PDE4 inhibitor, Tesuloid's development focused on achieving higher efficacy in moderate-to-severe disease and a distinct safety profile.

What is the typical duration of treatment with Tesuloid?

Treatment duration is generally long-term for chronic conditions like psoriasis. Patients are typically maintained on Tesuloid for as long as they demonstrate clinical benefit and tolerate the medication.

Are there any known drug interactions with Tesuloid?

Tesuloid is primarily metabolized by CYP3A4. Concomitant use with strong CYP3A4 inducers or inhibitors may require dose adjustments. A comprehensive list of drug interactions is available in the product's prescribing information.

What is the anticipated impact of biosimil competition on Tesuloid's pricing?

While Tesuloid is a small molecule and not subject to biosimilarity regulations, the availability of biosimil versions of competing biologic therapies will indirectly influence pricing strategies by increasing overall market price pressure.

When can generic versions of Tesuloid be expected?

Generic versions of Tesuloid are not expected to enter the market until after the expiration of its primary composition of matter patents, which are estimated to be between 2035 and 2037, barring any successful patent challenges or early terminations.

Citations

[1] STRIKE-1 Clinical Trial Results. (2023). Data on file. (Confidential internal study results provided by the drug manufacturer.) [2] Psoriasis Drug Pricing Report. (2024). PharmaMarket Insights Quarterly. (Market research report.)